A 55-year-old male with atrial fibrillation is prescribed warfarin for stroke prevention. The physician orders baseline INR and plans therapeutic drug monitoring. The structure marked **D** in the plasma concentration-time curve represents the area under the curve (AUC), which reflects total drug exposure and bioavailability. Which of the following best explains why therapeutic drug monitoring is essential for warfarin, and how AUC relates to its clinical use?

Explanation

## Why option 1 is correct Warfarin is a classic narrow-therapeutic-window drug requiring therapeutic drug monitoring via INR (International Normalized Ratio), not serum levels. The AUC (marked **D** in the diagram) reflects total systemic exposure to the drug. In warfarin's case, the AUC correlates with anticoagulant effect (INR). A subtherapeutic AUC results in inadequate anticoagulation and increased thrombotic risk (stroke, DVT), while a supratherapeutic AUC increases bleeding risk (GI bleed, intracranial hemorrhage). This is the fundamental principle of therapeutic drug monitoring for narrow-window drugs: maintaining AUC within a safe, effective range. Per KD Tripathi 9e Ch 3, warfarin is cited as a narrow-therapeutic-window drug requiring INR monitoring, and AUC is the basis of bioavailability and systemic exposure. ## Why each distractor is wrong - **Option 2**: Warfarin does NOT have 100% oral bioavailability. Although it has relatively good oral absorption (~95%), the statement that it is "completely absorbed" and that AUC monitoring ensures "adequate gastric pH for drug dissolution" is incorrect. Warfarin's bioavailability is not limited by gastric pH; it is a lipophilic weak acid absorbed well orally. AUC monitoring is not about pH. - **Option 3**: While warfarin does undergo hepatic metabolism (CYP2C9), it does NOT undergo extensive first-pass metabolism to the degree of nitroglycerin (F < 5%) or morphine. Warfarin's oral bioavailability is approximately 95%, not <5%. Furthermore, warfarin is not given IV in routine practice; dosing is oral. The statement conflates warfarin's metabolism with drugs like nitroglycerin that require sublingual/transdermal routes due to high first-pass loss. - **Option 4**: Warfarin is NOT eliminated unchanged in urine. It is metabolized hepatically to inactive metabolites and excreted in urine and bile. Ototoxicity is a concern with aminoglycosides and vancomycin (narrow-window drugs requiring peak/trough monitoring), not warfarin. This option confuses warfarin's pharmacokinetics with those of aminoglycosides. **High-Yield:** Warfarin requires INR monitoring (not serum level monitoring) because its AUC correlates with anticoagulant effect; it is a narrow-therapeutic-window drug where both under- and over-anticoagulation carry serious clinical consequences. [cite: KD Tripathi 9e Ch 3 — Pharmacokinetics; therapeutic drug monitoring for narrow-therapeutic-window drugs including warfarin]